# Xinguangwei Medical Technology (Suzhou) Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/xinguangwei-medical-technology-suzhou-co

- Industry: Medical Devices & Equipment
- Headquarters: Suzhou, China
- Website: www.scivitamedical.com
- Total disclosed funding: $124M
- Latest round: Series B (Aug 5, 2021)
- Investors on record: 9

## About

Xinguangwei Medical Technology (Suzhou) Co., Ltd. is a Chinese company specializing in the development and commercialization of innovative minimally invasive medical devices focused on enhancing clinical outcomes and operational efficiencies.Founded in 2016 in Suzhou, China, Xinguangwei Medical Technology develops advanced medical devices with a concentration on endoscopic technologies. The company has successfully raised CNY 400 million in its Series B round of funding on August 5, 2021, with contributions from GL Ventures, Hudson Bay Capital, Lilly Asia Ventures, MPC, and Prime Capital. The company has completed two deals, and there are no reports of subsidiaries or significant changes in business strategy since its inception.Xinguangwei Medical Technology Co., Ltd. specializes in the development and commercialization of minimally invasive medical devices, particularly focusing on endoscopic technologies. Their primary offerings include the 4KINSIGHT UHD Fluorescence Imaging System and a range of single-use videoscopes designed for various medical applications, such as urology, bronchoscopy, choledochoscopy, and hysteroscopy. These products are engineered to enhance diagnostic accuracy and treatment efficacy in clinical settings by providing high-definition imaging and facilitating precise interventions. Xinguangwei Medical's equipment addresses the needs of hospitals, surgical centers, and healthcare professionals globally, especially in regions such as North America, Europe, and Asia, thereby aiming to improve patient outcomes while promoting operational efficiencies in healthcare delivery.Xinguangwei Medical generates revenue through the direct sale of its advanced medical devices to healthcare institutions and professionals. The company employs a B2B transaction model, engaging in direct sales partnerships with hospitals and surgical centers, facilitating bulk purchases, and providing tailored support services. Their flagship products, such as the 4KINSIGHT UHD Fluorescence Imaging System, are positioned at the forefront of their revenue structure, catering to diverse medical specialties. Pricing strategies are developed to reflect the technology and clinical benefits offered by these devices, ensuring they meet the financial expectations of their client base while providing substantial value in diagnostic and therapeutic applications.In August 2021, Xinguangwei Medical Technology (Suzhou) Co., Ltd. raised CNY 400 million in Series B funding to support its ongoing research and development, capacity expansion, and both domestic and international commercialization of innovative products in endoscopy and related fields. Future product launches are anticipated, although specific release dates have not been disclosed. The company aims to strategically expand into new markets across North America and Europe within the next few years, leveraging the recent funding to enhance its product offerings and global presence.

## Funding rounds

- Series B, Aug 5, 2021, $62M — Lilly Asia Ventures, Hudson Bay Capital, Prime Capital, MPC, GL Ventures
- Series A, Apr 26, 2021, $62M — Chengwei Capital, Lilly Asia Ventures, MPC, ChuangVest Ventures, GL Ventures, Weilai Qichuang, Meizhong Capital Investment Management

## Investors

- Chengwei Capital (https://capitalatlas.ai/funds/chengwei-capital) — Series A
- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Series A, Series B
- MPC — Series A, Series B
- ChuangVest Ventures (https://capitalatlas.ai/funds/chuangvest-ventures) — Series A
- GL Ventures (https://capitalatlas.ai/funds/gl-ventures) — Series A, Series B
- Weilai Qichuang — Series A
- Meizhong Capital Investment Management (https://capitalatlas.ai/funds/meizhong-capital-investment-management) — Series A
- Hudson Bay Capital — Series B
- Prime Capital — Series B